. Author manuscript; available in PMC: 2017 Sep 1.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2016 Apr 23;96(1):65–71. doi: 10.1016/j.ijrobp.2016.04.020

TABLE 2.

Univariate analysis of local-regional recurrence-free interval.

	Invasive Cancers		All Patients^*

Parameter	Hazard Ratio (Range)	P-value	Hazard Ratio (Range)	P-value
ER-PR- vs. ER+/PR+ (invasive tumors)	0.81 (0.04–4.87)	0.8500	0.81 (0.04–4.79)	0.8482
Tumor subtype (DCIS vs. invasive)	-	-	0.53 (0.03–3.10)	0.5555
Body Mass Index	1.09 (0.98–1.19)	0.0886	1.09 (1.00–1.19)	0.0474
Bloom-Richardson grade (invasive tumors)	0.94 (0.35–2.58)	0.9094	1.13 (0.57–2.34)	0.7275
Tumor size	0.913 (0.33–1.79)	0.8323	1.06 (0.50–1.82)	0.8694
N stage	2.28 (0.33–10.59)	0.3250	2.47 (0.36–10.73)	0.2692
Chemotherapy (yes/no)	1.85 (0.41–9.38)	0.4227	2.01 (0.48–8.52)	0.3230
Diabetes at diagnosis	1.85 (0.10–10.85)	0.5712	1.67 (0.90–9.46)	0.6314
Age	0.976 (0.919–1.039)	0.4345	0.98 (0.92–1.04)	0.4877

Both invasive cancers and DCIS cases

Abbreviations: DCIS, ductal carcinoma in situ; ER/PR, estrogen receptor/progesterone receptor.